Hyperphosphatemic Familial Tumoral Calcinosis

Genetic Models of Deficient FGF23 Action

Lisal J. Folsom, Erik Imel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hyperphosphatemic familial tumoral calcinosis (hFTC) is a rare disorder of phosphate metabolism defined by hyperphosphatemia and ectopic calcifications in various locations. To date, recessive mutations have been described in three genes involving phosphate metabolism: FGF23, GALNT3, and α-Klotho, all of which result in the phenotypic presentation of hFTC. These mutations result in either inadequate intact fibroblast growth factor-23 (FGF23) secretion (FGF23 or GALNT3) or resistance to FGF23 activity at the fibroblast growth factor receptor/α-Klotho complex (α-Klotho). The biochemical consequence of limitations in FGF23 activity includes increased renal tubular reabsorption of phosphate, hyperphosphatemia, and increased production of 1,25-dihydroxyvitamin D. The resultant ectopic calcifications can be painful and debilitating. Medical treatments are targeted toward decreasing intestinal phosphate absorption or increasing phosphate excretion; however, results have been variable and generally limited. Treatments that would increase FGF23 levels or signaling would more appropriately target the genetic etiologies of this disease and perhaps be more effective.

Original languageEnglish
Pages (from-to)78-87
Number of pages10
JournalCurrent Osteoporosis Reports
Volume13
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Genetic Models
Phosphates
Hyperphosphatemia
Fibroblast Growth Factor Receptors
Mutation
Inborn Genetic Diseases
Intestinal Absorption
Hyperphosphatemic Familial Tumoral Calcinosis
fibroblast growth factor 23
Genes

Keywords

  • FGF23
  • Fibroblast growth factor 23
  • Hyperphosphatemia
  • Hyperphosphatemic familial tumoral calcinosis
  • Tumoral calcinosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Hyperphosphatemic Familial Tumoral Calcinosis : Genetic Models of Deficient FGF23 Action. / Folsom, Lisal J.; Imel, Erik.

In: Current Osteoporosis Reports, Vol. 13, No. 2, 2015, p. 78-87.

Research output: Contribution to journalArticle

@article{68166315c52f4723838f56a39f17e028,
title = "Hyperphosphatemic Familial Tumoral Calcinosis: Genetic Models of Deficient FGF23 Action",
abstract = "Hyperphosphatemic familial tumoral calcinosis (hFTC) is a rare disorder of phosphate metabolism defined by hyperphosphatemia and ectopic calcifications in various locations. To date, recessive mutations have been described in three genes involving phosphate metabolism: FGF23, GALNT3, and α-Klotho, all of which result in the phenotypic presentation of hFTC. These mutations result in either inadequate intact fibroblast growth factor-23 (FGF23) secretion (FGF23 or GALNT3) or resistance to FGF23 activity at the fibroblast growth factor receptor/α-Klotho complex (α-Klotho). The biochemical consequence of limitations in FGF23 activity includes increased renal tubular reabsorption of phosphate, hyperphosphatemia, and increased production of 1,25-dihydroxyvitamin D. The resultant ectopic calcifications can be painful and debilitating. Medical treatments are targeted toward decreasing intestinal phosphate absorption or increasing phosphate excretion; however, results have been variable and generally limited. Treatments that would increase FGF23 levels or signaling would more appropriately target the genetic etiologies of this disease and perhaps be more effective.",
keywords = "FGF23, Fibroblast growth factor 23, Hyperphosphatemia, Hyperphosphatemic familial tumoral calcinosis, Tumoral calcinosis",
author = "Folsom, {Lisal J.} and Erik Imel",
year = "2015",
doi = "10.1007/s11914-015-0254-3",
language = "English",
volume = "13",
pages = "78--87",
journal = "Current Alzheimer Research",
issn = "1546-9530",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Hyperphosphatemic Familial Tumoral Calcinosis

T2 - Genetic Models of Deficient FGF23 Action

AU - Folsom, Lisal J.

AU - Imel, Erik

PY - 2015

Y1 - 2015

N2 - Hyperphosphatemic familial tumoral calcinosis (hFTC) is a rare disorder of phosphate metabolism defined by hyperphosphatemia and ectopic calcifications in various locations. To date, recessive mutations have been described in three genes involving phosphate metabolism: FGF23, GALNT3, and α-Klotho, all of which result in the phenotypic presentation of hFTC. These mutations result in either inadequate intact fibroblast growth factor-23 (FGF23) secretion (FGF23 or GALNT3) or resistance to FGF23 activity at the fibroblast growth factor receptor/α-Klotho complex (α-Klotho). The biochemical consequence of limitations in FGF23 activity includes increased renal tubular reabsorption of phosphate, hyperphosphatemia, and increased production of 1,25-dihydroxyvitamin D. The resultant ectopic calcifications can be painful and debilitating. Medical treatments are targeted toward decreasing intestinal phosphate absorption or increasing phosphate excretion; however, results have been variable and generally limited. Treatments that would increase FGF23 levels or signaling would more appropriately target the genetic etiologies of this disease and perhaps be more effective.

AB - Hyperphosphatemic familial tumoral calcinosis (hFTC) is a rare disorder of phosphate metabolism defined by hyperphosphatemia and ectopic calcifications in various locations. To date, recessive mutations have been described in three genes involving phosphate metabolism: FGF23, GALNT3, and α-Klotho, all of which result in the phenotypic presentation of hFTC. These mutations result in either inadequate intact fibroblast growth factor-23 (FGF23) secretion (FGF23 or GALNT3) or resistance to FGF23 activity at the fibroblast growth factor receptor/α-Klotho complex (α-Klotho). The biochemical consequence of limitations in FGF23 activity includes increased renal tubular reabsorption of phosphate, hyperphosphatemia, and increased production of 1,25-dihydroxyvitamin D. The resultant ectopic calcifications can be painful and debilitating. Medical treatments are targeted toward decreasing intestinal phosphate absorption or increasing phosphate excretion; however, results have been variable and generally limited. Treatments that would increase FGF23 levels or signaling would more appropriately target the genetic etiologies of this disease and perhaps be more effective.

KW - FGF23

KW - Fibroblast growth factor 23

KW - Hyperphosphatemia

KW - Hyperphosphatemic familial tumoral calcinosis

KW - Tumoral calcinosis

UR - http://www.scopus.com/inward/record.url?scp=84925488112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925488112&partnerID=8YFLogxK

U2 - 10.1007/s11914-015-0254-3

DO - 10.1007/s11914-015-0254-3

M3 - Article

VL - 13

SP - 78

EP - 87

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1546-9530

IS - 2

ER -